Segall Bryant & Hamill LLC Has $47.61 Million Holdings in ICU Medical, Inc. (NASDAQ:ICUI)

Segall Bryant & Hamill LLC reduced its position in shares of ICU Medical, Inc. (NASDAQ:ICUI - Free Report) by 8.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 306,817 shares of the medical instruments supplier's stock after selling 26,627 shares during the period. ICU Medical makes up about 0.7% of Segall Bryant & Hamill LLC's portfolio, making the stock its 24th biggest holding. Segall Bryant & Hamill LLC owned approximately 1.25% of ICU Medical worth $47,609,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in ICUI. Barclays PLC increased its holdings in shares of ICU Medical by 15.6% during the third quarter. Barclays PLC now owns 59,207 shares of the medical instruments supplier's stock worth $10,790,000 after purchasing an additional 8,010 shares during the period. Principal Financial Group Inc. grew its position in ICU Medical by 24.6% during the third quarter. Principal Financial Group Inc. now owns 126,937 shares of the medical instruments supplier's stock worth $23,130,000 after buying an additional 25,031 shares in the last quarter. MetLife Investment Management LLC increased its stake in ICU Medical by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 12,389 shares of the medical instruments supplier's stock worth $2,258,000 after acquiring an additional 6,981 shares during the period. Jennison Associates LLC acquired a new position in ICU Medical in the 4th quarter valued at $556,000. Finally, Geode Capital Management LLC lifted its position in shares of ICU Medical by 9.6% during the 3rd quarter. Geode Capital Management LLC now owns 546,954 shares of the medical instruments supplier's stock valued at $99,687,000 after acquiring an additional 48,106 shares during the period. 96.10% of the stock is currently owned by institutional investors.

Remove Ads

Analyst Ratings Changes

ICUI has been the topic of a number of recent analyst reports. Jefferies Financial Group upgraded ICU Medical from a "hold" rating to a "buy" rating and set a $200.00 price target on the stock in a research report on Wednesday, December 11th. StockNews.com lowered shares of ICU Medical from a "buy" rating to a "hold" rating in a report on Thursday. Finally, Raymond James set a $97.00 price target on shares of ICU Medical in a report on Wednesday, March 12th. Two research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $168.67.

ICU Medical Price Performance

NASDAQ ICUI traded down $4.12 during trading on Friday, hitting $140.16. 224,230 shares of the company's stock were exchanged, compared to its average volume of 262,064. The company has a market cap of $3.44 billion, a PE ratio of -30.67 and a beta of 0.73. The company has a current ratio of 2.29, a quick ratio of 1.03 and a debt-to-equity ratio of 0.75. ICU Medical, Inc. has a fifty-two week low of $93.36 and a fifty-two week high of $196.26. The stock's 50 day moving average price is $154.42 and its two-hundred day moving average price is $163.82.

Insider Activity at ICU Medical

In related news, CEO Vivek Jain sold 1,373 shares of the business's stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $155.48, for a total transaction of $213,474.04. Following the sale, the chief executive officer now owns 104,593 shares in the company, valued at $16,262,119.64. The trade was a 1.30 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 6.70% of the stock is owned by insiders.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.